Chronic Kidney Disease Treatment Market Updates : The Drugs Segment Dominated the Market 2023-2032

According to a new report published by Allied Market Research, titled, "Chronic kidney disease treatment Market," The chronic kidney disease treatment market size was valued at $32 billion in 2022, and is estimated to reach $47.9 billion by 2032, growing at a CAGR of 4% from 2023 to 2032.

CAGR: 4%
Current Market Size: USD 32 Billion
Fastest Growing Region: APAC
Largest Market: North America
Projection Time: 2022-2032
Base Year: 2022

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭-https://www.alliedmarketresearch.com/request-sample/107605

Chronic kidney disease encompasses various conditions that inflict damage upon the kidneys, leading to a diminished capacity to effectively filter waste materials from the bloodstream, thereby compromising overall health. This prevalent ailment is frequently associated with the natural aging process, though it can affect individuals of any background. However, it exhibits a higher incidence among individuals of south Asian descent. The diagnosis of chronic kidney disease treatment primarily relies on blood and urine tests, which analyze the presence of elevated levels of specific substances in these bodily fluids. Such indicators serve as clear indications that the kidneys are not functioning optimally.

The major factors driving the growth of the chronic kidney disease treatment industry include rise in R&D activities for the launch of novel drugs and improvement in existing drugs. Moreover, the rise in the number of approvals from government regulatory institutes is creating lucrative opportunities for the chronic kidney disease treatment market. For instance, in April 2021, AstraZeneca, a global leading life science company, received approval from the U.S. FDA for Farxiga, a prescription medicine approved to reduce the risk of further worsening of initial stage kidney disease to end-stage kidney disease.

In addition, The increase in investment in research and development (R&D) activities has a significant impact on the demand for chronic kidney disease (CKD) drugs, creating lucrative opportunities for market growth. R&D plays a crucial role in the development of innovative drugs and therapies, which are essential in addressing the complex nature of chronic kidney disease and improving patient outcomes.

Furthermore, investments in R&D lead to advancements in drug discovery, formulation, and treatment options for CKD patients. Pharmaceutical companies, academic institutions, and research organizations are actively investing in R&D to explore new therapeutic targets, develop more effective drugs, and enhance existing treatment modalities. This increased focus on R&D activities is driven by the growing prevalence of CKD worldwide and the need for better treatment options.

Additionally, adoption of modern lifestyles characterized by sedentary habits, unhealthy diets, and high-stress levels have contributed to a rise in the incidence of CKD and its related conditions such as diabetes and hypertension. Unhealthy lifestyle choices, including a lack of physical activity and the consumption of processed foods high in salt, sugar, and saturated fats, have become prevalent in many populations. These lifestyle factors significantly contribute to the development and progression of CKD. As a result, there is a growing demand for chronic kidney disease treatment market trends to manage CKD and its complications.

However, side effects due to the treatments and expensive cost of dialysis are causing restrain in the market growth. Dialysis is a common treatment for CKD patients, but its high cost creates financial burdens for individuals and healthcare systems alike. The substantial expenses related to dialysis can limit access to treatment and negatively impact the demand for CKD drugs.

The chronic kidney disease treatment market analysis is segmented on the basis of treatment type, end user, and region. On the basis of treatment type, the market is divided into ACE inhibitors, calcium channel blockers, beta blockers, diuretics, and others. The dialysis segment occupied the highest chronic kidney disease treatment market share in 2022 and is expected to remain dominant during the forecast period owing to rising prevalence of CKD, advancements in dialysis technology, improved healthcare infrastructure, and increased accessibility to reimbursement policies.

However, the drugs segment is projected to register the highest CAGR during the forecast period. The advancements, including the introduction of new drugs and therapies, contribute significantly to the growth of the chronic kidney disease treatment market. Further, the availability of a diverse range of drug classes helps healthcare professionals tailor treatment plans to individual patient needs, driving improved outcomes and chronic kidney disease treatment industry.

By end user, the market is classified into hospitals, dialysis centers, ambulatory surgical centers, and others. The hospitals segment dominated the market in 2022 and is expected to remain dominant throughout the chronic kidney disease treatment market forecast. This is attributed to the growth as it is a primary healthcare provider and is often equipped with specialized departments and facilities dedicated to the diagnosis, treatment, and management of CKD.

North America dominated the chronic kidney disease treatment market share in 2022 and is expected to continue the trend throughout the forecast period. This is attributed to the rise in prevalence of CKD, presence of key players, and availability of high-quality healthcare system & modern medical technologies. However, Asia-Pacific is expected to register the highest CAGR during the forecast period, owing to the presence of a large patient population, growth in awareness about potential of chronic kidney disease treatment, and increase in healthcare funding.

𝑫𝒐 𝑷𝒖𝒓𝒄𝒉𝒂𝒔𝒆 𝑬𝒏𝒒𝒖𝒊𝒓𝒚- https://www.alliedmarketresearch.com/purchase-enquiry/A107121

𝑲𝒆𝒚 𝒇𝒊𝒏𝒅𝒊𝒏𝒈𝒔 𝒐𝒇 𝒕𝒉𝒆 𝒔𝒕𝒖𝒅𝒚 

On the basis of treatment, the drugs segment dominated the chronic kidney disease treatment market size in 2022. 

On the basis of end user, the hospital segment dominated the chronic kidney disease treatment market size in 2022. 

On the basis of region, North America dominated the market in 2022. However, Asia-Pacific is expected to be the fastest growing region during the forecast period. 

𝑹𝒆𝒄𝒆𝒏𝒕 𝑷𝒓𝒐𝒅𝒖𝒄𝒕 𝑨𝒑𝒑𝒓𝒐𝒗𝒂𝒍 𝒊𝒏 𝑪𝒉𝒓𝒐𝒏𝒊𝒄 𝒌𝒊𝒅𝒏𝒆𝒚 𝒅𝒊𝒔𝒆𝒂𝒔𝒆 𝒕𝒓𝒆𝒂𝒕𝒎𝒆𝒏𝒕 𝒎𝒂𝒓𝒌𝒆𝒕
In May 2023, AstraZeneca's Farxiga (dapagliflozin) received approval in the U.S. to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER Phase III trial.

In February 2023, AstraZeneca's Forxiga (dapagliflozin) received approval in the European Union to extend the indication for heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of left ventricular ejection fraction (LVEF), including HF with mildly reduced and preserved ejection fraction (HFmrEF, HFpEF).

In September 2022, AstraZeneca's Forxiga received approval in China to reduce the risk of sustained estimated glomerular filtration rate ((eGFR)) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression with and without type-2 diabetes (T2D).

In April 2022, Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, received the U.S. Food and Drug Administration (FDA) clearance for the VersiPD Cycler System1. This next-generation portable automated peritoneal dialysis system is the lightest, smallest, and quietest dialysis cycler in the U.S.

𝑹𝒆𝒄𝒆𝒏𝒕 𝑨𝒄𝒒𝒖𝒊𝒔𝒊𝒕𝒊𝒐𝒏 𝒊𝒏 𝑪𝒉𝒓𝒐𝒏𝒊𝒄 𝒌𝒊𝒅𝒏𝒆𝒚 𝒅𝒊𝒔𝒆𝒂𝒔𝒆 𝒕𝒓𝒆𝒂𝒕𝒎𝒆𝒏𝒕 𝒎𝒂𝒓𝒌𝒆𝒕

In March 2022, B. Braun SE, one of the world's leading medical technology companies acquired Intermedt Medizin &; Technik GmbH, a specialist in the preparation of dialysis concentrates. With this acquisition the Intermedt product portfolio will be permanently integrated into B. Braun comprehensive range of products and services for dialysis therapy.

𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞- https://www.alliedmarketresearch.com/chronic-kidney-disease-treatment-market-A107121

𝑶𝒕𝒉𝒆𝒓 𝑻𝒓𝒆𝒏𝒅𝒊𝒏𝒈 𝑹𝒆𝒑𝒐𝒓𝒕𝒔 𝒊𝒏 𝑳𝒊𝒇𝒆 𝑺𝒄𝒊𝒆𝒏𝒄𝒆 𝑫𝒐𝒎𝒂𝒊𝒏-

𝑴𝒆𝒅𝒊𝒄𝒂𝒍 𝑻𝒂𝒑𝒆 𝑴𝒂𝒓𝒌𝒆𝒕 https://www.alliedmarketresearch.com/medical-tape-market-A17081

𝑴𝒊𝒄𝒓𝒐𝒃𝒊𝒐𝒎𝒆 𝑺𝒆𝒒𝒖𝒆𝒏𝒄𝒊𝒏𝒈 𝑴𝒂𝒓𝒌𝒆𝒕 https://www.alliedmarketresearch.com/microbiome-sequencing-market-A13576

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.